New Perspectives of Treatment With Fesoterodine Fumarate in Patients With Overactive Bladder

被引:4
作者
Garcia-Baquero, R. [1 ]
Madurga, B. [1 ]
Garcia, M. V. [2 ]
Fernandez, M. A. [2 ]
Rosety, J. M. [1 ]
Alvarez-Ossorio, J. L. [1 ]
机构
[1] Hosp Univ Puerta Mar, Unidad Gest Clin Urol, Unidad Urol Func, Cadiz, Spain
[2] Hosp Univ Puerta Mar, Serv Med Prevent, Cadiz, Spain
来源
ACTAS UROLOGICAS ESPANOLAS | 2013年 / 37卷 / 02期
关键词
Fesoterodine; Intolerance; Overactive bladder; MIXED URINARY-INCONTINENCE; TOLTERODINE EXTENDED-RELEASE; PLACEBO-CONTROLLED TRIAL; HEAD-TO-HEAD; MUSCARINIC RECEPTORS; SMOOTH-MUSCLE; EFFICACY; SAFETY; URGE; WOMEN;
D O I
10.1016/j.acuro.2012.05.008
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objective: Evaluate the effect of the treatment with fesoterodine fumarate in patients with overactive bladder, as an alternative in case of failure of the usual anticholinergic treatment, due to either lack of therapeutic efficacy or due to intolerance to side effects. Material and method: A retrospective review of 158 patients with overactive bladder was carried out. The patients were divided into two groups; the first group; 56 patients where the anticholinergic treatment showed to be ineffective, and the second group; 102 patients who presented intolerance to anticholinergic side effects. Results: For the first group where fesoterodine fumarate was used to improve effectiveness of the anticholinergics, improvement in the components of urinary urgency (p = 0.001), insufficient emptying (p = 0.001), incontinence (p = 0.009), and in the number of pads/day (p < 0.001) was detected. As to the second group where fesoterodine fumarate was used as an alternative to anticholinergics to avoid side effects, a high reduction in the incidence of dry mouth (p <0.001) and constipation (p = 0.015) was seen, as well as a significant clinical improvement. Conclusion: Fesoterodine fumarate is an optimal treatment option when the clinical response to anticholinergics has not been satisfactory, either by the lack of therapeutic action or by intolerance to side effects, and especially when the treatment is expected to be long. (c) 2012 AEU. Published by Elsevier Espana, S.L. All rights reserved.
引用
收藏
页码:83 / 91
页数:9
相关论文
共 38 条
[1]   Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder [J].
Abrams, Paul ;
Andersson, Karl-Erik ;
Buccafusco, Jerry J. ;
Chapple, Christopher ;
de Groat, William Chet ;
Fryer, Alison D. ;
Kay, Gary ;
Laties, Alan ;
Nathanson, Neil M. ;
Pasricha, Pankaj Jay ;
Wein, Alan J. .
BRITISH JOURNAL OF PHARMACOLOGY, 2006, 148 (05) :565-578
[2]   Antimuscarinics for treatment of overactive bladder [J].
Andersson, KE .
LANCET NEUROLOGY, 2004, 3 (01) :46-53
[3]   Influence of CYP2D6 polymorphism on the pharmacokinetics and pharmacodynamics of tolterodine [J].
Brynne, N ;
Dalén, P ;
Alván, G ;
Bertilsson, L ;
Gabrielsson, J .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (05) :529-539
[4]  
Castro D., 2005, Archivos Espanoles de Urologia, V58, P131
[5]  
Castro D, 2011, ACTAS UROL ESP, V35, P73, DOI [10.1016/S2173-5786(11)70022-1, 10.1016/j.acuro.2010.11.011]
[6]   Clinical efficacy, safety, and tolerability of once-daily fesoterodine in subjects with overactive bladder [J].
Chapple, Christopher ;
Van Kerrebroeck, Philip ;
Tubaro, Andrea ;
Haag-Molkenteller, Cornelia ;
Forst, Hans-Theo ;
Massow, Ute ;
Wang, Joseph ;
Brodsky, Marina .
EUROPEAN UROLOGY, 2007, 52 (04) :1204-1212
[7]   Comparison of fesoterodine and tolterodine in patients with overactive bladder [J].
Chapple, Christopher R. ;
Van Kerrebroeck, Philip E. ;
Juenemann, Klaus-Peter ;
Wang, Joseph T. ;
Brodsky, Marina .
BJU INTERNATIONAL, 2008, 102 (09) :1128-1132
[8]   The effects of antimuscarinic treatments in overactive bladder: An update of a systematic review and meta-analysis [J].
Chapple, Christopher R. ;
Khullar, Vik ;
Gabriel, Zahava ;
Muston, Dominic ;
Bitoun, Caty Ebel ;
Weinstein, David .
EUROPEAN UROLOGY, 2008, 54 (03) :543-562
[9]   The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro [J].
Chess-Williams, R ;
Chapple, CR ;
Yamanishi, T ;
Yasuda, K ;
Sellers, DJ .
JOURNAL OF AUTONOMIC PHARMACOLOGY, 2001, 21 (5-6) :243-248
[10]   Fesoterodine, an advanced antimuscarinic for the treatment of overactive bladder: A safety update [J].
Cole, P .
DRUGS OF THE FUTURE, 2004, 29 (07) :715-720